Mohamed Tashani1, Sanjay Jayasinghe1, Zitta B Harboe1, Harunor Rashid1, Robert Booy1. 1. Mohamed Tashani, Sanjay Jayasinghe, Harunor Rashid, Robert Booy, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, the Children's Hospital at Westmead, Sydney 2145, Australia.
Abstract
AIM: To investigate evidence of clinical protection in infants after one dose of 7-valent pneumococcal conjugate vaccine (7vPCV) owing to carrier priming. METHODS: Using Australian National Notifiable Diseases Surveillance System data, we conducted a descriptive analysis of cases of vaccine type invasive pneumococcal disease (VT-IPD) during "catch-up" years, when 7vPCV was carrier primed by prior administration of DTPa vaccine. We compared the number of VT-IPD cases occurring 2-9 wk after a single dose of 7vPCV (carrier primed), with those < 2 wk post vaccination, when no protection from 7vPCV was expected yet. Further comparison was conducted to compare the occurrence of VT-IPD cases vs non-VT-IPD cases after a single carrier-primed dose of 7vPCV. RESULTS: We found four VT-IPD cases occurring < 2 wk after one carrier primed dose of 7vPCV while only one case occurred 2-9 wk later. Upon further comparison with the non-VT-IPD cases that occurred after one carrier primed dose of 7vPCV, two cases were detected within 2 wk, whereas seven occurred within 2-9 wk later; suggesting a substantial level of protection from VT-IPD occurring from 2 wk after carrier-primed dose of 7vPCV. CONCLUSION: This data suggest that infants may benefit from just one dose of 7vPCV, likely through enhanced immunity from carrier priming effect. If this is proven, an adjusted 2-dose schedule (where the first dose of PCV is not given until after DTPa) may be sufficient and more cost-effective.
AIM: To investigate evidence of clinical protection in infants after one dose of 7-valent pneumococcal conjugate vaccine (7vPCV) owing to carrier priming. METHODS: Using Australian National Notifiable Diseases Surveillance System data, we conducted a descriptive analysis of cases of vaccine type invasive pneumococcal disease (VT-IPD) during "catch-up" years, when 7vPCV was carrier primed by prior administration of DTPa vaccine. We compared the number of VT-IPD cases occurring 2-9 wk after a single dose of 7vPCV (carrier primed), with those < 2 wk post vaccination, when no protection from 7vPCV was expected yet. Further comparison was conducted to compare the occurrence of VT-IPD cases vs non-VT-IPD cases after a single carrier-primed dose of 7vPCV. RESULTS: We found four VT-IPD cases occurring < 2 wk after one carrier primed dose of 7vPCV while only one case occurred 2-9 wk later. Upon further comparison with the non-VT-IPD cases that occurred after one carrier primed dose of 7vPCV, two cases were detected within 2 wk, whereas seven occurred within 2-9 wk later; suggesting a substantial level of protection from VT-IPD occurring from 2 wk after carrier-primed dose of 7vPCV. CONCLUSION: This data suggest that infants may benefit from just one dose of 7vPCV, likely through enhanced immunity from carrier priming effect. If this is proven, an adjusted 2-dose schedule (where the first dose of PCV is not given until after DTPa) may be sufficient and more cost-effective.
Authors: Barbara E Mahon; Katherine Hsu; Sudharani Karumuri; Sheldon L Kaplan; Edward O Mason; Stephen I Pelton Journal: Vaccine Date: 2005-12-27 Impact factor: 3.641
Authors: Judith Spijkerman; Reinier H Veenhoven; Alienke J Wijmenga-Monsuur; Karin E M Elberse; Pieter G M van Gageldonk; Mirjam J Knol; Hester E de Melker; Elisabeth A M Sanders; Leo M Schouls; Guy A M Berbers Journal: JAMA Date: 2013-09-04 Impact factor: 56.272
Authors: Hope L Johnson; Maria Deloria-Knoll; Orin S Levine; Sonia K Stoszek; Laura Freimanis Hance; Richard Reithinger; Larry R Muenz; Katherine L O'Brien Journal: PLoS Med Date: 2010-10-05 Impact factor: 11.069
Authors: F M Russell; A Balloch; M L K Tang; J R Carapetis; P Licciardi; J Nelson; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; G B Byrnes; Y B Cheung; E K Mulholland Journal: Vaccine Date: 2009-07-17 Impact factor: 3.641
Authors: Igor Rudan; Katherine L O'Brien; Harish Nair; Li Liu; Evropi Theodoratou; Shamim Qazi; Ivana Lukšić; Christa L Fischer Walker; Robert E Black; Harry Campbell Journal: J Glob Health Date: 2013-06 Impact factor: 4.413
Authors: Shabir A Madhi; Eleonora Aml Mutsaerts; Alane Izu; Welekazi Boyce; Sutika Bhikha; Benit T Ikulinda; Lisa Jose; Anthonet Koen; Amit J Nana; Andrew Moultrie; Lucy Roalfe; Adam Hunt; David Goldblatt; Clare L Cutland; Jeffrey R Dorfman Journal: Lancet Infect Dis Date: 2020-08-25 Impact factor: 25.071